$OKUR News

OnKure Therapeutics Reports First Quarter 2026 Financial Results

OnKure Therapeutics Q1 EPS $(1.11) Misses $(0.64) Estimate

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

OnKure Therapeutics Enters Into Securities Purchase Agreement For Private Placement Raising Gross Proceeds Of ~$150M

'[HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $27

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

OnKure Therapeutics Q4 EPS $(0.99) Misses $(0.75) Estimate

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics Q3 EPS $(1.09) Beats $(1.22) Estimate

OnKure Therapeutics Q3 EPS $(1.09) Beats $(1.22) Estimate

OnKure Therapeutics to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $34 Price Target

Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky

OnKure Therapeutics shares are trading higher after the company reported a Q2 EPS beat.

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics Q2 EPS $(1.14) Beats $(1.26) Estimate

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate

HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $34

Will OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?